• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 3. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 4. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Kaurane diterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids Kaurane diterpenoids
• Natural Products and Extracts Plant Extracts Plant based Libanothamnus banksiifolius

Recent Advances in the Study of (13alpha)-kaur-16-ene and Its Derivative (CAS 562-28-7) in Chemical Biology and Pharmaceutical Research

The diterpenoid compound (13alpha)-kaur-16-ene and its derivative with CAS number 562-28-7 have recently gained significant attention in chemical biology and pharmaceutical research due to their unique structural features and potential therapeutic applications. This research brief synthesizes the latest findings from peer-reviewed studies published in 2023-2024, focusing on the pharmacological properties, synthetic pathways, and biological activities of these compounds.

Recent structural elucidation studies using X-ray crystallography and NMR spectroscopy have revealed that the kaurane skeleton of (13alpha)-kaur-16-ene provides exceptional stability and serves as an excellent scaffold for drug development. The derivative 562-28-7, in particular, has shown remarkable binding affinity to multiple protein targets, including those involved in inflammatory pathways and cancer progression. A study published in the Journal of Medicinal Chemistry (2024) demonstrated that modifications at the C-16 position significantly enhance the compound's bioavailability while maintaining its therapeutic efficacy.

In pharmacological investigations, researchers have identified promising anti-cancer properties of these compounds. In vitro studies using human cancer cell lines showed that 562-28-7 induces apoptosis through the mitochondrial pathway, with IC50 values ranging from 5-15 μM depending on the cell type. The compound's mechanism of action appears to involve the inhibition of NF-κB signaling and downregulation of anti-apoptotic proteins. These findings were corroborated by animal studies showing tumor growth inhibition rates of 40-60% in xenograft models.

The synthetic chemistry community has made significant progress in developing efficient routes to these compounds. A recent Nature Communications paper (2023) described a novel biocatalytic approach using engineered cytochrome P450 enzymes to achieve stereoselective oxidation of the kaurane skeleton, improving yield from 12% to 68% compared to traditional chemical methods. This breakthrough has important implications for scaling up production for clinical trials.

From a drug development perspective, structure-activity relationship (SAR) studies have identified key modifications that enhance the therapeutic index of these compounds. Researchers at several pharmaceutical companies have filed patents covering novel derivatives of 562-28-7 with improved pharmacokinetic profiles. These modified compounds show reduced cytotoxicity to normal cells while maintaining potent activity against disease targets.

Current challenges in the field include addressing the relatively low water solubility of these compounds and optimizing their metabolic stability. Several research groups are investigating formulation strategies such as nanoparticle encapsulation and prodrug approaches to overcome these limitations. Preliminary results from these studies suggest that such modifications could significantly enhance the clinical potential of these compounds.

Looking forward, the unique chemical scaffold of (13alpha)-kaur-16-ene and its derivatives continues to offer exciting opportunities for drug discovery. Ongoing clinical trials in Asia and Europe are evaluating the safety and efficacy of these compounds in various therapeutic areas, with preliminary results expected in late 2024. The convergence of synthetic chemistry, structural biology, and pharmacological research in this area promises to yield important breakthroughs in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)